Comparison of baseline characteristics of patients with presumably normal liver and NAFLD
| Presumably normal liver (n=179) | NAFLD (n=619) | p Value* | |
|---|---|---|---|
| Demographic | |||
| Age at surgery (year) | 37.0 (35.3 to 38.7) | 44.4 (43.5 to 45.3) | <0.0001 |
| Age at onset of obesity (year) | 14.8 (12.6 to 16.9) | 20.0 (18.8 to 21.2) | <0.0001 |
| Duration of obesity (year) | 22.1 (20.0 to 24.2) | 24.0 (22.9 to 25.0) | ns |
| Female gender | 164 (92%) | 455 (73%) | <0.0001 |
| Caucasian | 72 (40%) | 449 (81%) | <0.0001 |
| Clinical | |||
| Hypertension | 50 (29%) | 318 (53%) | <0.0001 |
| Type 2 diabetes mellitus | 17 (11%) | 249 (48%) | <0.0001 |
| Dyslipidemia | 54 (31%) | 334 (55%) | <0.0001 |
| Obstructive sleep apnoea | 25 (14%) | 240 (39%) | <0.0001 |
| Anthropometric | |||
| BMI (kg/m2) | 45.9 (44.7 to 47.1) | 47.8 (47.3 to 48.4) | <0.01 |
| Weight (kg) | 127 (123.9 to 130.2) | 132.7 (130.8 to 134.7) | <0.01 |
| Waist circumference (cm) | 165.8 (164.7 to 167.1) | 166.4 (165.6 to 167.1) | ns |
| Body fat mass (%) | 50.0 (49.2 to 50.7) | 48.4 (47.9 to 48.8) | <0.001 |
| Trunk/limb fat mass | 1.00 (0.97 to 1.04) | 1.27 (1.24 to 1.30) | <0.0001 |
| Liver function tests | |||
| ALT (IU/L) | 24.3 (19.8 to 28.7) | 39.1 (36.7 to 41.5) | <0.0001 |
| AST (IU/L) | 23.8 (22.2 to 25.4) | 30.9 (29.7 to 32.1) | <0.0001 |
| GGT (IU/L) | 37.5 (31.2 to 43.8) | 53.9 (46.1 to 61.8) | <0.01 |
| Laboratory parameters | |||
| Fasting glucose (mmol/L) | 5.2 (5.0 to 5.4) | 6.5 (6.3 to 6.7) | <0.0001 |
| Haemoglobin A1C (%) | 5.9 (5.7 to 6.0) | 6.6 (6.5 to 6.7) | <0.0001 |
| Fasting insulin (µU/mL) | 15.1 (13.6 to 16.5) | 25.1 (21.9 to 28.3) | <0.0001 |
| Total cholesterol (mmol/L) | 4.9 (4.7 to 5.0) | 4.8 (4.7 to 4.9) | ns |
| HDL cholesterol (mmol/L) | 1.3 (1.2 to 1.3) | 1.2 (1.1 to 1.2) | <0.0001 |
| Triglycerides (mmol/L) | 1.2 (1.1 to 1.3) | 1.7 (1.6 to 1.8) | <0.0001 |
Data are given as mean (95% CI) or n (%).
*p for comparison between healthy liver and NAFLD.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ-glutamyl transpeptidase; HDL, high-density lipoprotein; IU, international unit; NAFLD, non-alcoholic fatty liver disease; ns, not significant; Y, year.